Back to top

Zacks.com featured highlights include article Kraton, aTyr Pharma, Grupo Financiero Galicia, Grupo Supervielle and Calithera Biosciences

Read MoreHide Full Article

For Immediate Release

Chicago, IL – October 11, 2017 - Stocks in this week’s article Kraton Corporation (NYSE: (KRA - Free Report)  – Free Report), aTyr Pharma, Inc. (Nadsaq: (LIFE - Free Report)  – Free Report), Grupo Financiero Galicia S.A. (Nadsaq: (GGAL - Free Report)  – Free Report), Grupo Supervielle S.A. (NYSE: (SUPV - Free Report)  – Free Report) and Calithera Biosciences, Inc. (Nadsaq: (CALA - Free Report)  – Free Report).

Screen of the Week of Zacks Investment Research by:

5 Stocks to Add to Your Portfolio on New Analyst Coverage

Many investors have immense faith in research work by analysts as they fear that lack of information while exploring on their own might trigger inefficiencies. Here, analysts play a vital intermediary role with their extensive access to relevant data.

Coverage initiation of a stock by analyst(s) usually portrays higher investor inclination. Investors, on their part, often assume there is something special in a stock to attract analysts to cover it. In other words, they believe that the company coming under the microscope definitely has some value.

Obviously, stocks are not randomly chosen to cover. New coverage on a stock usually reflects a reassuring future envisioned by the analyst(s). At times, increased investors’ focus on a stock motivates analysts to take a closer look at it. After all, who doesn’t love to produce something that is already in demand? Hence, we often find that analysts’ ratings on newly added stocks are more favorable than their ratings on continuously covered stocks.

It is needless to say, the average change in broker recommendation is more preferable than a single recommendation change.

How Does Analyst Coverage Influence Stock Price?

The price movement of a stock is generally a function of the recommendations on it from new analysts. Stocks typically see an upward price movement with a new analyst coverage compared to what is witnessed with a rating upgrade under an existing coverage. Positive recommendations – Buy and Strong Buy – generally lead to a significantly positive price reaction than Hold recommendations. On the contrary, analysts hardly initiate coverage with a Strong Sell or Sell recommendation.

Now, if an analyst gives a new recommendation on a company that has very few or no existing coverage, investors start paying more attention to it. Also, any new information attracts portfolio managers to build a position in the stock.

So, it’s a good strategy to bet on stocks that have seen increased analyst.

Screening Criteria

Number of Broker Ratings now greater than the Number of Broker Ratings four weeks ago (This will shortlist stocks that have recent new coverage).

Average Broker Rating less than Average Broker Rating four weeks ago ('Less than' means 'better than' four weeks ago).

Increased analyst coverage and improving average rating are the primary criteria of this strategy but one should consider other relevant parameters to make the strategy foolproof.

Here are the other screening parameters:

Price greater than or equal to $5 (as a stock below $5 will not likely create significant interest for most investors).

Average Daily Volume greater than or equal to 100,000 shares (if volume isn’t enough, it will not attract individual investors).

Here are five of the 14 stocks that passed the screen:

Kraton Corporation (NYSE: (KRA - Free Report) – Free Report) makes styrenic block copolymers, specialty polymers and performance products derived from pine wood pulping co-products. The stock has climbed 42.6% year to date, while the industrygained 10.3%. The stock carries a Zacks Rank #1 (Strong Buy) and has seen earnings estimates move up 2.4% for this year and 4.5% for 2018 over the past 60 days. Positive earnings estimate revisions for 2017 and 2018 indicate the stock’s potential for price appreciation.

aTyr Pharma, Inc. (Nadsaq: (LIFE - Free Report) – Free Report), a bio-therapeutics company, has gained more than 155% this year, compared with its industry’s 14.1%. The company’s current year as well as next year’s loss estimates have narrowed over the last 60 days.

Grupo Financiero Galicia S.A. (Nadsaq: (GGAL - Free Report) – Free Report), a financial and investment services holding company, has returned more than 96% so far this year, compared with its industry’s 19.4%. The stock carries a Zacks Rank #3 (Hold) and it has an expected growth rate of 15% for 2017 and 12.7% for 2018.

Grupo Supervielle S.A. (NYSE: SUPVFree Report) is a private domestically-owned financial group. The stock has gained almost 82% year to date, compared with its industry’s 19.4%. The stock holds a Zacks Rank #3 and a VGM Score of A. It saw positive earnings estimate revision of 2.3% for this year and 2.2% for 2018 over the past 30 days. It has an expected growth rate of 28.4% for 2017 and 31.1% for 2018.

Calithera Biosciences, Inc. (Nadsaq: CALAFree Report) is a clinical-stage pharmaceutical company. The stock has skyrocketed 433.9% year to date, significantly outperforming the industry’s 3.1% gain. Loss estimates have narrowed to 88 cents from 96 cents for 2017 over the last 60 days, with an expected growth rate of a 54.9%. The stock has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance.

Zacks Restaurant Recommendations: In addition to dining at these special places, you can feast on their stock shares. A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector. Download it free »

Sign up now for your free trial today and start picking better stocks immediately. And with the backtesting feature, you can test your ideas to see how you can improve your trading in both up markets and down markets. Don’t wait for the market to get better before you decide to do better. Start learning how to be a better trader today: https://at.zacks.com/?id=111

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use. Each week, Zacks Profit from the Pros free email newsletter shares a new screening strategy. Learn more about it here https://at.zacks.com/?id=112

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time!Click here for your free subscription to Profit from the Pros.

Get the full Report on KRA - FREE

Get the full Report on LIFE - FREE

Get the full Report on GGAL - FREE

Get the full Report on SUPV - FREE

Get the full Report on CALA - FREE

Follow us on Twitter:  https://twitter.com/zacksresearch

Join us on Facebook:  https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: pr@zacks.com

Visit: https://www.zacks.com/performance

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.



More from Zacks Press Releases

You May Like